Helping the lives of people with the greatest need by combining breakthrough science and cutting-edge product development. #globalhealth
Cambridge, MA
Joined July 2017
- Tweets625
- Following264
- Followers3.2K
- Likes208
We must address challenges like vaccine adherence and strain variation to create more effective malaria interventions.
Read more on recent perspectives in the clinical development of malaria vaccines in @Nature: nature.com/articles/s41467-0…
Earlier this year, Uganda became the 19th country in Africa to adopt a malaria vaccine, marking the largest malaria vaccine roll-out to date. the-star.co.ke/health/2025-0…
A recent study presented at @ESCMID revealed that more than 3 million children, particularly in Southeast Asia and Africa, died from antimicrobial resistant (AMR) infections in 2022.
Read more about the threat here: gavi.org/vaccineswork/more-3…
New genetic studies suggest that distinct strains of malaria exist in different areas of Africa, making some intervention tactics less effective.
Major challenges remain in recruiting enough scientists with the expertise to help track these strains. gavi.org/vaccineswork/qa-unl…
There is an urgent need to tackle rising rates of TB across the globe. In 2023, 8.2M people were diagnosed with TB. If proven well tolerated and efficacious, the M72/AS01E vaccine candidate could be the first new TB vaccine in 100 years.
Read more from @GSK in this BBC StoryWorks piece. GSK, as well as @wellcometrust and @gatesfoundation, is a partner of the Phase 3 clinical trial for the M72/AS01E vaccine candidate. bbc.com/storyworks/innovatio…
MDR-TB threatens global TB prevention, with cases highest in 15- to 19-year-olds and deaths greatest in children ages <5. Read more to better understand global trends in MDR-TB: nature.com/articles/s41390-0…
TB cases among children under 15 in the @WHO European region rose to 7,500– 650 more than in 2022. Increased travel & better diagnostics play a role, but more substantial global TB funding is critical to prevent further setbacks. reuters.com/business/healthc…
Treatment of TB disease is complicated by the rise of antimicrobial resistance (AMR). Reads how genomic data can predict AMR, helping clinicians tailor and improve TB treatment: nature.com/articles/s41598-0…
Tuberculosis (TB) remains a global health challenge. Our own Alemnew Dagnew led a study using Group-Based Trajectory Modeling to track TB notification patterns over time, identifying geographic clusters to strengthen intervention strategies.
Read more: bmcpublichealth.biomedcentra…
The Phase 3 trial of the M72/AS01E tuberculosis (TB) vaccine candidate has reached full enrollment, with approx. 20,000 participants across 5 countries, a major step in this important trial.
More in @statnews: statnews.com/2025/04/28/majo…
Gates Medical Research Institute retweeted
With full enrollment of the Phase 3 clinical trial of the M72/AS01E TB vaccine candidate ahead of schedule, we're one step closer to what could be, if proven well tolerated and efficacious, the first new TB vaccine in over a century.
To tackle public health threats, local scientists need access to the right resources.
ClinOps provides African scientists with clinical trial training to enhance research and innovation. By investing in programs like this, we can advance global health. bmcmededuc.biomedcentral.com…
We're glad to announce the Phase 3 trial of the M72/AS01E TB vaccine is fully enrolled. Thanks to all our partners and trial participants, we’re closer to understanding the safety and efficacy of the candidate. A novel TB vaccine is critical to the vision of a world without TB.
A study found resistance to the malaria drug artemisinin in Uganda. 11 out of 100 kids had repeat infections within 28 days, showing partial resistance. We must prioritize innovative solutions to tackle this rising threat. nature.com/articles/d44148-0…
The @FDA granted Breakthrough Device Designation to @intelligenome’s CRISPR-Tuberculosis (TB) Blood Test. This test uses CRISPR tech to detect TB in blood samples, which could help with public screening and early diagnosis of TB. biospace.com/press-releases/…
The rollout of the R21/Matrix-M vaccine in Nigeria can help protect children against malaria and offers hope to families throughout the country and region. With government and community support, Nigeria is making progress against malaria. gavi.org/vaccineswork/nigeri…
After decades of research and implementation, the @WHO has officially declared Georgia malaria-free. Effective health care policies, mosquito control and treatments have led the WHO European Region to eliminate malaria for future generations. who.int/news/item/23-01-2025…
Gates Medical Research Institute retweeted
TB is the leading infectious killer but scientific breakthroughs could change that.
On #WorldTBDay, I spoke with @GatesMRI CEO Patrice Matchaba about what’s ahead - from the M72 vaccine candidate to new diagnostics & drugs.
Continued global collaboration is essential to #EndTB
Today marks one year since launching the Phase 3 clinical trial of the M72/AS01E tuberculosis (TB) vaccine candidate. The trial has 54 sites in five countries.
